Xiu-Qing Zhang

Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7

These proof-of-concept findings demonstrate that stable peptide–MHC binding is a necessary but insufficient condition for optimal T-cell activation and provides a proof-of-concept strategy for further preclinical evaluation of HPV16-targeted peptide-based immunotherapies.